Summary
The pharmacokinetics of dexamethasone, given at low dose, were studied in 13 patients with congenital adrenal hyperplasia (CAH) to ascertain whether kinetics differed in this inherited disorder of cortisol metabolism from those seen in healthy individuals.
Changes in plasma dexamethasone concentration after intravenous bolus, measured using a simple novel radioimmunoassay, were well described by a two-compartment open model with first-order kinetics. Values for λ2: 0.206 h−1, t1/2: 3.53 h, Vc: 24.41 and f: 0.64 were similar to those previously reported for normal subjects. There were considerable interindividual differences in parameter values and Cmaxp.o. (range 22–67 nmol/l).
As suppression of the hypothalamo-pituitary-adrenal axis correlates with plasma dexamethasone levels, this variability may partly explain the differing dose and dose schedule requirements necessary to achieve adequate therapeutic control in the clinical management of CAH.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
White PC, New MI, Dupont B (1987) Congenital adrenal hyperplasia. N Engl J Med 316: 1519–1586
Hughes IA (1988) Management of congenital adrenal hyperplasia. Arch Dis Child 63: 1399–1404
Horrocks PM, London DR (1987) Effects of long-term dexamethasone treatment in adult patients with congenital adrenal hyperplasia. Clin Endocrinol 27: 635–642
Hansten PD (1979) Corticosteroids and enzyme inducers. Drug Intell Clin Pharm 13: 577–578
APBI Data sheet compendium 1988–89. Datapharm Publications, London, p 929
Seth J, Brown LM (1978) A simple radioimmunoassay for plasma cortisol. Clin Chim Acta 86: 109–120
Hunter WM, Nars PW, Rutherford FJ (1975) Preparation and behaviour of125I-labeled radioligand for phenolic and neutral steroids. In: Cameron EHD, Hillier SG, Griffiths K (eds) Steroid immunoassay: Proceedings of the 5th Tenovus Workshop, April 1974. Alpha Omega, Cardiff, UK
Aronson JK, Dengler HJ, Dettli L, Follath F (1988) Standardization of symbols in clinical pharmacology. Eur J Clin Pharmacol 35: 1–7
Rohdewald P, Mollman H, Barth J, Rehder J, Derendorf H (1987) Pharmacokinetics of dexamethasone and its phosphate ester. Biopharm Drug Dispos 8: 205–212
Hare LE, Yeh KC, Ditzler CA, MacMahon FG, Duggan DE (1975) Bioavailability of dexamethasone II. Dexamethasone phosphate. Clin Pharm Ther 18: 330–337
Duggan DE, Yeh KC, Ditzler CA, McMahon FG (1975) Bioavailability of oral dexamethasone. Clin Pharm Ther 18: 205–209
Melby JC, Dale SL (1969) Comparison of absorption, disposal and activity of soluble and repository corticosteroid esters. Clin Pharm Ther 10: 344–350
Brady ME, Sartiano GP, Rosenblum SL, Zaglama NE, Bauguens CT (1987) The pharmacokinetics of single high doses of dexamethasone in cancer patients. Eur J Clin Pharmacol 32: 593–596
Loew D, Schuster O, Graul EH (1986) Dose dependent pharmacokinetics of dexamethasone. Eur J Clin Pharmacol 30: 225–230
Feely J, Brodie MJ (1988) Practical clinical pharmacology: Drug handling and response. Br Med J 296: 1096–1050
Ballard PL (1979) Delivery and transport of glucocorticoid to target cells. In: Baxter JD, Rousseau GG (eds) Glucocorticoid action. Monographs in endocrinology. Springer, Berlin Heidelberg New York
Lowy MT, Meltzer HY (1987) Dexamethasone bioavailability: Implications for DST research. Biol Psychiatry 22: 373–385
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Young, M.C., Cook, N., Read, G.F. et al. The pharmacokinetics of low-dose dexamethasone in congenital adrenal hyperplasia. Eur J Clin Pharmacol 37, 75–77 (1989). https://doi.org/10.1007/BF00609429
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00609429